IP Library Granted Patent US 8,124,087
Granted Patent B2
US 8,124,087 · App. 12/008,771 · Granted Feb 28, 2012

Methods of controlling bone loss by inhibiting DKK1

Assignee: Board of Trustees of the University of Arkansas
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,124,087
App. No.
12/008,771
Granted
Feb 28, 2012
Kind
B2
Abstract

The present invention is drawn to understanding lytic bone diseases. In this regard, the present invention discloses mechanism by which Wnt signaling antagonist inhibits bone differentiation. Also disclosed herein are methods to control bone loss, treat bone disease and prevent tumor growth in bones of individual.

Claims (9)

1. A method of controlling bone loss characterized by increased DKK1 expression in an individual, comprising the step of:

administering to said individual a pharmacologically effective amount of a DKK1 specific antibody that binds a DKK1 protein consisting of the amino acid sequence encoded by the DKK1 gene of SEQ ID NO: 47, wherein said administration inhibits DKK1 at the protein level, and prevents further bone loss in the individual.

2. The method of claim 1 , wherein said inhibition of DKK1 blocks induction of Wnt ligand, restores RANK/OPG levels, or both.

3. The method of claim 1 , wherein said individual has post-menopausal osteoporosis.

4. The method of claim 1 , wherein said bone loss is caused by breast cancer metastasis to the bone or prostate cancer metastasis to the bone.

5. A method of treating bone disease characterized by increased DKK1 expression in an individual, comprising the step of:

administering to said individual a pharmacologically effective amount of a DKK1 specific antibody that binds a DKK1 protein consisting of the amino acid sequence encoded by the DKK1 gene of SEQ ID NO: 47, such that said administration blocks induction of Wnt ligand, restores RANK/OPG levels, or both.

6. The method of claim 5 , wherein said individual has post-menopausal osteoporosis.

7. The method of claim 5 , wherein said bone disease is caused by breast cancer metastasis to the bone or prostate cancer metastasis to the bone.

Assignments (3)
CORRECTIVE DOCUMENT REEL/FRAME: 023542/0206 ASSIGNEE'S NAME. Recorded Jan 16, 2012
From: SHAUGHNESSY, JOHN D.; BARLOGIE, BART; QIANG, YA-WEI
To: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Reel/Frame 027549/0400 →
CONFIRMATORY LICENSE Recorded Sep 17, 2010
From: UNIVERSITY OF ARKANSAS MED SCIS LTL ROCK
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025004/0897 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2009
From: SHAUGHNESSY, JOHN D.; BARLOGIE, BART; QIANG, YA-WEI
To: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, THE
Reel/Frame 023542/0206 →
Continuity (4)
Continuation In Part 11176739 · Jul 7, 2005
Continuation In Part 10727461 · Dec 4, 2003
Provisional Application 60431040 · Dec 5, 2002
Related Publication 20080267950A1 · Oct 30, 2008